Paying users zone. Data is covered by .
Get to Gilead Sciences Inc. for $17.99, or
get to entire website for at least 3 months from $49.99.
Gilead Sciences Inc. (GILD)
Enterprise Value to EBITDA (EV/EBITDA)
Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)
Gilead Sciences Inc., EBITDA calculation
USD $ in millions
|EBITDA||To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital.||Gilead Sciences Inc.’s EBITDA declined from 2016 to 2017 and from 2017 to 2018.|
Enterprise Value to EBITDA Ratio, Current
Gilead Sciences Inc., current EV/EBITDA calculation, comparison to benchmarks
|Selected Financial Data (USD $ in millions)|
|Enterprise value (EV)|
|Earnings before interest, tax, depreciation and amortization (EBITDA)|
|Bristol-Myers Squibb Co.|
|Eli Lilly & Co.|
|Johnson & Johnson|
|Merck & Co. Inc.|
|Regeneron Pharmaceuticals Inc.|
|Pharmaceuticals & Biotechnology|
Based on: 10-K (filing date: 2019-02-26).
If company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.
Enterprise Value to EBITDA Ratio, Historical
Gilead Sciences Inc., historical EV/EBITDA calculation, comparison to benchmarks
3 EV/EBITDA = EV ÷ EBITDA
= ÷ =
|EV/EBITDA||EV/EBITDA is a valuation indicator for the overall company rather than common stock.||Gilead Sciences Inc.’s EV/EBITDA ratio increased from 2016 to 2017 and from 2017 to 2018.|